Why one-drug companies are back in fashion

For much of the past decade, biotech companies sold investors on scale and future potential. Discovery engines, synthetic biology platforms, gene-editing systems and AI-led pipelines were presented as technologies capable of generating entire portfolios of medicines over time. The investment case often depended less on one product than on the promise that a platform could repeatedly produce new ones.